1h Free Analyst Time
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Sodium- and chloride-dependent glycine transporter 1 is a protein encoded by the SLC6A9 gene. It terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals. It plays a role in regulation of glycine levels in NMDA receptor-mediated neurotransmission.Speak directly to the analyst to clarify any post sales queries you may have.
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Hematological Disorders and Metabolic Disorders which include indications Schizophrenia, Cognitive Impairment Associated With Schizophrenia (CIAS), Bipolar Disorder (Manic Depression), Dyskinesia, Memory Impairment, Parkinson's Disease, Pervasive Developmental Disorder (PDD), Porphyria (Erythropoietic Protoporphyri) and Unspecified Hematological Disorders.
The latest report, outlays comprehensive information on the Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)
- The report reviews Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics and enlists all their major and minor projects
- The report assesses Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Overview
- Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Companies Involved in Therapeutics Development
- AbbVie Inc
- Boehringer Ingelheim International GmbH
- ConSynance Therapeutics Inc
- Dart NeuroScience LLC
- Disc Medicine Inc
- Mental-Heal Ltd
- Pfizer Inc
- Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Drug Profiles
- bitopertin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CSTI-200 - Drug Profile
- Product Description
- Mechanism Of Action
- DNS-006 - Drug Profile
- Product Description
- Mechanism Of Action
- iclepertin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PF-03463275 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PGW-5 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit GlyT1 for Parkinson’s Disease and Schizophrenia - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Glyt1 for Schizophrenia - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit Glyt1 for Unspecified Hematological Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VU-0410120 - Drug Profile
- Product Description
- Mechanism Of Action
- Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Dormant Products
- Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Discontinued Products
- Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Product Development Milestones
- Featured News & Press Releases
- Nov 03, 2022: Disc Medicine announces presentations on Bitopertin across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting
- Oct 31, 2022: Disc Medicine initiates AURORA, a phase 2 clinical study of Bitopertin in adults with Erythropoietic Protoporphyria (EPP)
- Aug 10, 2022: Disc Medicine initiates BEACON, a phase 2 clinical study of Bitopertin in patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)
- Nov 11, 2021: Disc Medicine announces oral presentation on bitopertin at the 63rd American Society of Hematology Annual Meeting
- May 24, 2021: Boehringer Ingelheim's investigational treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
- Sep 15, 2020: Boehringer’s drug improves cognition in Phase II schizophrenia trial
- Jan 21, 2014: Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia
- Dec 06, 2010: Phase II Study With First-In-Class Investigational Drug Demonstrates Improvement In Negative Symptoms In Patients With Schizophrenia
- Dec 06, 2010: Roche Announces Eight-Week Results From Phase II Study Of RG16781 In Patients With Schizophrenia
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by AbbVie Inc, 2022
- Pipeline by Boehringer Ingelheim International GmbH, 2022
- Pipeline by ConSynance Therapeutics Inc, 2022
- Pipeline by Dart NeuroScience LLC, 2022
- Pipeline by Disc Medicine Inc, 2022
- Pipeline by Mental-Heal Ltd, 2022
- Pipeline by Pfizer Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Boehringer Ingelheim International GmbH
- ConSynance Therapeutics Inc
- Dart NeuroScience LLC
- Disc Medicine Inc
- Mental-Heal Ltd
- Pfizer Inc
